SC 13G/A | 2024-02-14 | EcoR1 Capital, LLC | Atea Pharmaceuticals, Inc. | 6,995,861 | 8.4% | EDGAR |
SC 13G/A | 2024-02-14 | EcoR1 Capital, LLC | Atea Pharmaceuticals, Inc. | 6,995,861 | 8.4% | EDGAR |
SC 13G/A | 2024-02-14 | EcoR1 Capital, LLC | Atea Pharmaceuticals, Inc. | 6,995,861 | 8.4% | EDGAR |
SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Atea Pharmaceuticals, Inc. | 4,599,710 | 5.5% | EDGAR |
SC 13G/A | 2024-02-13 | Sommadossi Jean-Pierre | Atea Pharmaceuticals, Inc. | 5,925,000 | 7.1% | EDGAR |
SC 13G/A | 2024-02-09 | FMR LLC | Atea Pharmaceuticals, Inc. | 5,350,659 | 6.4% | EDGAR |
SC 13G/A | 2024-02-07 | BML Investment Partners, L.P. | Atea Pharmaceuticals, Inc. | 5,462,079 | 6.5% | EDGAR |
SC 13G | 2024-02-07 | BML Investment Partners, L.P. | Atea Pharmaceuticals, Inc. | 5,462,079 | 6.5% | EDGAR |
SC 13G/A | 2024-01-24 | BlackRock Inc. | Atea Pharmaceuticals, Inc. | 9,443,887 | 11.3% | EDGAR |
SC 13D/A | 2023-11-28 | TANG CAPITAL PARTNERS LP | Atea Pharmaceuticals, Inc. | 4,033,463 | 4.8% | EDGAR |
SC 13G/A | 2023-11-07 | BlackRock Inc. | Atea Pharmaceuticals, Inc. | 8,838,015 | 10.6% | EDGAR |
SC 13G | 2023-10-02 | BML Investment Partners, L.P. | Atea Pharmaceuticals, Inc. | 4,183,645 | 5.0% | EDGAR |
SC 13G/A | 2023-09-11 | FMR LLC | Atea Pharmaceuticals, Inc. | 7,074,287 | 8.5% | EDGAR |
SC 13D | 2023-05-22 | TANG CAPITAL PARTNERS LP | Atea Pharmaceuticals, Inc. | 3,026,455 | 3.6% | EDGAR |
SC 13G/A | 2023-02-10 | EcoR1 Capital, LLC | Atea Pharmaceuticals, Inc. | 6,184,861 | 7.4% | EDGAR |
SC 13G/A | 2023-02-10 | Sommadossi Jean-Pierre | Atea Pharmaceuticals, Inc. | 5,925,000 | 7.1% | EDGAR |
SC 13G/A | 2023-02-09 | FMR LLC | Atea Pharmaceuticals, Inc. | 11,737,409 | 14.1% | EDGAR |
SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Atea Pharmaceuticals, Inc. | 6,089,522 | 7.3% | EDGAR |
SC 13G/A | 2023-01-24 | BlackRock Inc. | Atea Pharmaceuticals, Inc. | 8,033,572 | 9.6% | EDGAR |
SC 13G/A | 2022-02-16 | Morningside Venture Investments Ltd | Atea Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |